Browsing by Subject "Cancer survival"
Now showing items 1-20 of 141
-
Article
Adjuvant Cytotoxic and Endocrine Therapy in Pre- and Postmenopausal Patients with Breast Cancer and One to Nine Infiltrated Nodes: Five-Year Results of the Hellenic Cooperative Oncology Group Randomized HE 10/92 Study
(2004)The present randomized phase III trial was designed to detect a 15% benefit in relapse-free survival (RFS) or overall survival (OS) from the incorporation of adjuvant tamoxifen to the combination of CNF [cyclophosphamide, ...
-
Article
Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience
(2006)Purpose.: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study ...
-
Article
Axillary nodal metastases from carcinoma of unknown primary (CUPAx): A systematic review of published evidence
(2010)Axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary (CUPAx) represent a rare clinical entity without consensus on its biology, management and outcome. We systematically ...
-
Article
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: Interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
(2013)Background: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order ...
-
Article
Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature
(2005)Background: Brain metastases from epithelial ovarian cancer (EOC) are rare. A retrospective study of all patients diagnosed with brain metastases from EOC over the last 20 years, according to the Hellenic Cooperative ...
-
Article
Brain metastasis of unknown primary: A diagnostic and therapeutic dilemma
(2005)The diagnosis of a brain metastasis is usually made during the routine follow up examinations of patients with known cancer, who are under the care of oncology departments. The involvement of the neurosurgeon depends on ...
-
Article
Cancer of unknown primary during pregnancy: An exceptionally rare coexistence
(2015)Background: Cancer in pregnancy is a rare disease with breast cancer, cervical cancer, melanoma and Hodgkin's disease to be the most commonly diagnosed malignancies during gestation. Cancer of unknown primary (CUP) is a ...
-
Article
Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer
(2015)Cancer of Unknown Primary (CUP) comprises a heterogeneous disease group with diagnosis of metastatic malignancy in the absence of an identifiable primary site after diagnostic work up. CUP may either resemble a specific ...
-
Article
Cancer of unknown primary site
(2012)Cancer of unknown primary site (CUP) is a well recognised clinical disorder, accounting for 3-5 of all malignant epithelial tumours. CUP is clinically characterised as an aggressive disease with early dissemination. ...
-
Article
Cancer of unknown primary site: 20 questions to be answered
(2010)Cancer of unknown primary (CUP) is a common, well-recognized and heterogeneous clinical syndrome. Patients with CUP present with metastatic disease in the absence of an identifiable primary tumour despite a diagnostic ...
-
Article
-
Article
-
Article
Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study
(2000)Purpose: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). Patients and Methods: Seventy-seven consecutive CUP patients (45 women and 32 men; median ...
-
Article
Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?
(2005)Carcinoma of unknown primary (CUP) is characterized by dismal patient survival. The outcome of patients with two favourable risk CUP subsets was studied. Eighty patients diagnosed with either midline lymph node metastases ...
-
Article
Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study
(1994)The efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation were prospectively assessed in patients with small cell lung cancer. Both combinations were equally ...
-
Article
Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients
(1996)A total of 209 postsurgical breast cancer patients were prospectively monitored with simultaneous serum level estimations of CA 15-3, mucin-like carcinoma-associated antigen (MCA), tumor polypeptide antigen (TPA), and ...
-
Article
Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma
(2006)The aim of the study was to investigate angiogenesis in patients with advanced-stage ovarian carcinoma. We used paraffin-embedded tumor tissues from 33 patients diagnosed with FIGO III ovarian cancer who had optimal surgery ...
-
Article
Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer
(2003)Expression of the hormone-related proteins hsp27, pS2, and also of cathepsin D (CD) and metallothionein (MT) was studied by immunohistochemistry and analyzed against clinical data in breast cancer. Archived material of ...
-
Article
Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A prospective study
(1997)From June 1984 to October 1995, forty seven consecutive patients (pts) with a confirmed diagnosis of diffuse malignant mesothelioma (MM) of the pleura (41) and peritoneum (6), were treated with cisplatin (CDDP) (24 pts) ...
-
Article
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group
(2005)To investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were ...